1. Show article details.

    BRIEF-Cidara Therapeutics Added To Russell 3000® Index

    Reuters – 8:12 AM ET 06/29/2020

    Cidara Therapeutics Inc (CDTX): * CIDARA THERAPEUTICS ADDED TO RUSSELL 3000® INDEX Source text for Eikon: Further company coverage:

  2. Show article details.

    Cidara Therapeutics Added to Russell 3000® Index

    GlobeNewswire – 8:00 AM ET 06/29/2020

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that it has been added to the Russell 3000® Index at the conclusion of the Russell indexes annual reconstitution, effective upon the U.S. market open today, June 29, 2020.

  3. Show article details.

    Cidara Therapeutics to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19

    GlobeNewswire – 8:00 AM ET 06/23/2020

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the Cantor Fitzgerald “Winning Ways to Treat Infections and COVID-19” Virtual Symposium on Tuesday, June 30, 2020.

  4. Show article details.

    Cidara Therapeutics to Present at the Raymond James Human Health Innovations Conference

    GlobeNewswire – 8:00 AM ET 06/11/2020

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present virtually at the Raymond James Human Health Innovations Conference on Thursday, June 18, 2020.

  5. Show article details.

    BRIEF-Cidara Therapeutics Files Prospectus Relating To Offer, Resale By Selling Stockholder Of Up To 4.78 Mln Shares

    Reuters – 9:23 AM ET 06/05/2020

    Cidara Therapeutics Inc (CDTX): * CIDARA THERAPEUTICS SAYS IT FILES PROSPECTUS RELATING TO OFFER, RESALE BY SELLING STOCKHOLDER OF UP TO 4.78 MILLION SHARES OF COMMON STOCK - SEC FILING Source: Further company coverage:

  6. Show article details.

    BRIEF-Cidara Therapeutics Doses First Patient In Pivotal Trial Of Rezafungin

    Reuters – 8:45 AM ET 05/20/2020

    Cidara Therapeutics Inc (CDTX): * CIDARA THERAPEUTICS (CDTX) - DOSES FIRST PATIENT IN PIVOTAL PHASE 3 RESPECT TRIAL OF REZAFUNGIN Source text: Further company coverage:

  7. Show article details.

    Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

    GlobeNewswire – 8:45 AM ET 05/20/2020

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal candidate, rezafungin, for the preve...

  8. Show article details.

    BRIEF-Cidara Therapeutics Posts Quarterly Loss Per Share $0.46

    Reuters – 5:35 PM ET 05/13/2020

    Cidara Therapeutics Inc (CDTX): * CIDARA PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS. * Cidara Therapeutics Inc (CDTX) - NET LOSS FOR THE THREE MONTHS ENDED MARCH 31, 2020 WAS $14.5 MILLION. * Cidara Therapeutics Inc (CDTX) - QTRLY LOSS PER SHARE $0.46 Source text for Eikon: Further company coverage:

  9. Show article details.

    Cidara Provides Corporate Update and Reports First Quarter 2020 Financial Results

    GlobeNewswire – 4:52 PM ET 05/13/2020

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended March 31, 2020, and provided an update on its corporate activities and product pipeline.

  10. Show article details.

    BRIEF-Cidara Therapeutics Announces New Clinical And Preclinical Data For Rezafungin And Influenza Avcs From The ECCMID

    Reuters – 5:59 PM ET 05/05/2020

    Cidara Therapeutics Inc (CDTX): * CIDARA THERAPEUTICS ANNOUNCES NEW CLINICAL AND PRECLINICAL DATA FOR REZAFUNGIN AND INFLUENZA AVCS FROM THE EUROPEAN CONGRESS OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES Source text for Eikon: Further company coverage:

  11. Show article details.

    Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs from the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    GlobeNewswire – 4:30 PM ET 05/05/2020

    Abstract Book highlights new data from Cidara accepted for presentation at ECCMID 2020  Phase 2 trial shows superiority of rezafungin in time to clear deadly infection Seven abstracts highlight new data on influenza antiviral conjugates from Cloudbreak® antiviral platform  SAN DIEGO, May 05, 2020 -- Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transf...

  12. Show article details.

    Cidara Therapeutics to Participate in Antifungal and COVID-19 Therapeutics Panels at Maxim Group’s Infectious Disease Virtual Conference

    GlobeNewswire – 8:00 AM ET 04/28/2020

    Cidara Therapeutics, Inc. (CDTX), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in two panels discussing antifungal and COVID-19 therapies at the upcoming Infectious Disease Virtual Conference presented by Maxim Group.

  13. Show article details.

    Cidara Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference

    GlobeNewswire – 8:00 AM ET 04/07/2020

    Cidara Therapeutics, Inc. (CDTX), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present at the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2020.

  14. Show article details.

    Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results

    GlobeNewswire – 5:55 AM ET 03/04/2020

    Cidara Therapeutics, Inc. (CDTX), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives, reported financial results for the three months and full year ended December 31, 2019, and provided an update on its corporate activities and product pipeline.

  15. Show article details.

    Cidara Therapeutics to Present at Transplantation & Cellular Therapy (TCT) and Mycology 2020 Medical Conferences

    GlobeNewswire – 8:00 AM ET 02/18/2020

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing therapeutics to improve the standard of care for patients facing severe fungal or viral infections, today announced that it will present a poster at the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood & Marrow Transplant Research, whic...

  16. Show article details.

    Cidara Therapeutics Announces Closing of Rights Offering

    GlobeNewswire – 5:30 PM ET 02/12/2020

    Cidara Therapeutics, Inc. (CDTX) today announced the closing of its previously announced rights offering. The Rights Offering was made pursuant to Cidara’s effective shelf registration statement on file with the Securities and Exchange Commission and a prospectus supplement and accompanying prospectus filed with the SEC on January 22, 2020.

  17. Show article details.

    Cidara Therapeutics Announces Commencement of Rights Offering

    GlobeNewswire – 7:55 AM ET 01/22/2020

    Cidara Therapeutics, Inc. (CDTX) today commenced the previously announced rights offering to raise gross proceeds of approximately $30.0 million.

  18. Show article details.

    Cidara Therapeutics Announces Proposed Rights Offering

    GlobeNewswire – 8:00 AM ET 01/10/2020

    Rights Offering will be available to all stockholders and 2018 warrant holders of record on January 21, 2020 $30.0 million to be raised, fully backstopped Cidara Therapeutics, Inc. (CDTX) today announced its intent to raise $30.0 million through a fully backstopped rights offering.

Page:

Today's and Upcoming Events

  • Aug
    10

    CDTX to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    13

    CDTX announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.